Asset Details
Do you wish to reserve the book?
Clinical and Pharmacoeconomic evaluation of Fidaxomicin in patients over 65 years of age and immunocompromised patients with recurrent and refractory Clostridioides difficile infection
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Clinical and Pharmacoeconomic evaluation of Fidaxomicin in patients over 65 years of age and immunocompromised patients with recurrent and refractory Clostridioides difficile infection
Do you wish to request the book?
Clinical and Pharmacoeconomic evaluation of Fidaxomicin in patients over 65 years of age and immunocompromised patients with recurrent and refractory Clostridioides difficile infection
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Clinical and Pharmacoeconomic evaluation of Fidaxomicin in patients over 65 years of age and immunocompromised patients with recurrent and refractory Clostridioides difficile infection
2026
Overview
Background
Recurrent or refractory
Clostridioides difficile
infection (CDI) often affects older and immunocompromised patients, posing clinical and economic challenges. While fidaxomicin has shown lower recurrence rates than vancomycin in the general population, evidence in this population remains limited.
Methods
This retrospective, multicentre case-control study compared patients aged > 65 years or immunocompromised patients receiving fidaxomicin (case group) with those treated with vancomycin (control group) for recurrent or refractory CDI. A microcosting approach was used to assess direct treatment costs.
Results
A total of 344 patients were included (172 per group). Compared to the control group, the fidaxomicin group presented a significantly higher rate of symptom reduction on day 10 (
n
= 163, 95% vs.
n
= 147, 86%;
p
= 0.004) and lower CDI recurrence rates (
n
= 36, 21% vs.
n
= 63, 37%;
p
= 0.001). While the mean CDI treatment costs per patient were significantly higher in the fidaxomicin group (
p
< 0.001), the hospitalisation and overall treatment costs were comparable (€19,898, 95% CI €16,151-€23,645 vs. €20,469, 95% CI €16,837-€24,101,
p
= 0.811; €17,798, 95% CI €14,620-€20,975 vs. €17,300, 95% CI €14,199-€20,400,
p
= 0.840). Key cost drivers were hospitalisation, intensive care unit treatment, and severe initial CDI.
Conclusions
Despite higher drug acquisition costs of fidaxomicin, overall treatment costs were comparable between the two groups with better clinical outcomes in patients treated with fidaxomicin.
Clinical trial number
Not applicable.
Publisher
BioMed Central,BioMed Central Ltd,Springer Nature B.V,BMC
Subject
/ Aged
/ Anti-Bacterial Agents - economics
/ Anti-Bacterial Agents - therapeutic use
/ Clostridioides difficile - drug effects
/ Clostridioides difficile infection
/ Clostridium Infections - drug therapy
/ Clostridium Infections - economics
/ Clostridium Infections - microbiology
/ Complications and side effects
/ Diarrhea
/ Disease
/ Diseases
/ DRGs
/ Female
/ Fidaxomicin - therapeutic use
/ Healthcare resource utilization
/ Humans
/ Male
/ Medicine
/ Patients
/ Relapse
